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Edited by Horst FeldmannAbstract The completion of the Drosophila genome sequencing
project [Science 287 (2000) 2185] has reconﬁrmed the fruit ﬂy as
a model organism to study human disease. Comparison studies
have shown that two thirds of genes implicated in human cancers
have counterparts in the ﬂy [Curr. Opin. Genet. Dev. 11 (2001)
274; J. Cell Biol. 150 (2000) F23], including the tumour
suppressor, p53. The suitability of the fruit ﬂy to study the
function of the tumour suppressor p53 is further exempliﬁed by
the lack of p53 family members within the ﬂy genome, i.e., no
homologues to p63 and p73 have been identiﬁed. Hence, there is
no redundancy between family members greatly facilitating the
analysis of p53 function. In addition, studying p53 in Drosophila
provides an opportunity to learn about the evolution of tumour
suppressors. Here, we will discuss what is known about
Drosophila p53 in relation to human p53.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The human p53 transcription factor is a 393 amino acid
protein consisting of a N-terminal transactivation domain
(amino acids 1–83), a central sequence-speciﬁc DNA binding
domain (amino acids 102–292), and a C-terminal oligomeri-
zation domain (amino acids 324–355). Hundreds of studies are
dedicated to elucidating the functions of p53. This is because
although p53 is not essential for normal growth and develop-
ment, it plays a pivotal role in tumour suppression. Indeed,
loss of normal p53 function occurs in almost all human cancers
[4].
At present there is agreement on a model describing the
general mode of p53 function: p53 is inactive in normal cells. It
is rapidly activated by various types of stress signals which
cause oncogenic alterations, such as DNA damage, hypoxia or
nucleotide depletion. p53 activation results in the execution of
transcriptional programmes which either result in cell cycle
arrest, allowing time for damage repair, or cause the oﬀending
cell to be destroyed by apoptosis. However, the molecular
mechanisms underlying p53 activation, cell cycle arrest and
apoptosis have not been fully elucidated.* Corresponding author. Fax: +49-89-5996-425.
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As mentioned above, p53 functions as an inhibitor of cell
growth, by inducing cell cycle arrest or apoptotic cell death [5].
Hence, the activity of p53 must be tightly regulated in order to
allow both normal growth and tumour suppression, and the
transition between these states. p53 is regulated at both the
translational and transcriptional level [6]. However, there
are three mechanisms, which shall be discussed below, which
are the major determinants of p53 activation; controlling the
protein levels of p53, its cellular localization, and lastly its
ability to function as a sequence-speciﬁc transcription factor.
All of which are regulated by posttranslational modiﬁcations.1.2. p53 protein stability
In normal unstressed cells, p53 is a short-lived protein,
which is maintained at low, often undetectable levels in the
cell. Tight regulation of the abundance of p53 is required for
normal growth and development. In the absence of stress-in-
ducing signals, p53 is kept at low levels via its interaction with
mouse double minute 2 (MDM2), an ubiquitin ligase. Upon
binding to the N-terminus of p53, MDM2 transfers ubiquitin
moieties to several sites within the C-terminus of p53. The
ubiquitinated p53 is subsequently exported from the nucleus
and degraded by the proteasome [7]. The expression of MDM2
is under the control of p53, hence, this negative feedback loop
provides a means of keeping the level of p53 low in unstressed
cells, and reducing the level of p53 in stressed cells, once the
damage has been repaired [8,9].
It should be noted that proteasome-independent p53 deg-
radation pathways do exist in human cells as well: for example,
calpains, a family of ubiquitous cysteine proteases that is
conserved between ﬂies and man, degrade p53. Furthermore,
calpain inhibitors can induce apoptosis under certain circum-
stances [10–12].
In response to cellular stress signals, p53 is activated, and
this increase in activity is accompanied by an increase in the
stability of the protein. As the p53/MDM2 interaction is im-
portant for maintaining a low concentration of p53, it is also
critical for increasing the levels of p53. Hence, several path-
ways which activate p53 impinge upon the p53/MDM2 inter-
action. Upon cellular stress, kinases belonging to the
phosphatidylinositol-3-kinase family are activated. For exam-
ple, in response to ionizing radiation (IR), ataxia-telangiecta-
sia-mutated (ATM) is activated and phosphorylates various
proteins [13]. Ataxia-telangiectasia-and-Rad3-related (ATR) is
upregulated in response to incomplete DNA replication [14].
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Fig. 1. Regulation of p53 stability and subcellular localization upon
response to stress signals, p53 is phosphorylated, causing the release of
MDM2, and inhibition of nuclear export signals resulting in stabil-
ization and activation of p53.
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nisms, wherein ATM and ATR interact with damaged DNA,
and indirect mechanisms, whereby they interact with DNA
repair or maintenance proteins have been proposed [15]. These
kinases can activate p53 by both direct and indirect methods:
ATM/ATR can phosphorylate p53 at Serine 15, which results
in an increase in p53 stability. Alternatively, they initiate a
phosphorylation cascade; ATM and ATR target the eﬀector
kinases checkpoint-homologues Chk2 and Chk1, respectively,
which function during checkpoint control during the cell cycle
(for a recent review of Chk1 and Chk2 see [16]). Chk1 and
Chk2 subsequently phosphorylate p53, resulting in the release
of MDM2 from p53. Hence, the interaction between MDM2
and p53 is disrupted, and MDM2 can no longer target p53 for
ubiquitination.
In addition to targeting p53 for phosphorylation, the ATM
kinase can also modify MDM2. Although this phosphoryla-
tion occurs outside of the p53 binding region, this modiﬁcation
abrogates its interaction with p53 [17]. Indeed other kinases,
such as DNA-PK, also phosphorylate MDM2 and abolish its
ability to interact with p53 [18]. In addition to phosphorylation
there are other means which result in p53 stabilization. For
example, in response to DNA damage c-Abl can bind to and
stabilize p53. This association does not prevent MDM2 from
binding p53, but prevents p53 from being ubiquitinated by
MDM2 [19].
1.3. Localization of p53
In addition to stability, p53 is regulated by where it is in the
cell. As p53 functions as a transcription factor, localization of
p53 to the nucleus plays a key role in regulating its activity.
There are various mechanisms which can import p53 into, or
export it out of the nucleus. The means for transporting p53
into the nucleus are two fold; ﬁrstly, p53 can be transported
into the nucleus by dynein and the microtubule network, which
requires the N-terminus of p53 [20]. Secondly, within the C-
terminus of p53 reside various nuclear localization signals
which are recognized by nuclear import factors [6]. Upon en-
tering the nucleus there are mechanisms to export p53 back
into the cytoplasm. These take the form of two export se-
quences: one within the C-terminal oligomerization domain
[21] and another in the N-terminal MDM2 binding region [22].
Whilst the export of p53 is not MDM2-dependent, MDM2
does contribute to this eﬀect, via its ubiquitin ligase activity. In
the tetramerized form the C-terminal nuclear export signal is
not accessible to the export pathway, hence, it could be spec-
ulated that, upon ubiquitination, the C-terminal export signal
is exposed, and p53 can move to the cytoplasm [23].
The N-terminal nuclear export signal is regulated by phos-
phorylation, insomuch as phosphorylation inhibits the nuclear
export sequence. Hence, the eﬀects of N-terminal p53 phos-
phorylation to retain p53 in the nucleus are two fold: ﬁrstly by
inhibiting the N-terminal export signal, and secondly by in-
hibiting binding by MDM2 and subsequently reducing ubiq-
uitination and activation of the C-terminal export signal
(Fig. 1).
1.4. Regulation of p53 activity
p53 exerts its eﬀects by both transcriptional and non-tran-
scriptional mechanisms [6]. Best understood is p53’s role as a
classical transcription factor, upregulating the expression of
genes which function to arrest the cell cycle, for example thecyclin-dependent kinase inhibitor p21 (CIP/KIP), or induce
apoptosis, such as Bax1. How p53 distinguishes between in-
voking cell cycle arrest or apoptosis is at present ill-under-
stood. However, it has been suggested that cofactors which
associate with p53 help make this decision, such as JMY
(junction-mediated and regulatory protein [24]), and apoptosis
stimulating protein p53-1 (ASPP1) and ASPP2 [25]. Expres-
sion of ASPP2 stimulates recruitment of p53 to the pro-ap-
optotic Bax gene following UV treatment. By contrast, p53
binding to the cell cycle arrest gene p21 is not aﬀected under
these conditions.
The stimulation of p53’s transcription factor function;
binding DNA and interacting with the transcriptional ma-
chinery, is mediated, in part by posttranslational modiﬁcations
(for a comprehensive review see [26]).
Within p53 there are two speciﬁc regions which are targeted
for posttranslational modiﬁcations, one in the N-terminus
which can undergo phosphorylation, and one in the C-termi-
nus which can be acetylated, phosphorylated, glycosylated and
sumoylated, each modiﬁcation aﬀects p53 activity [6].
As mentioned above, phosphorylation within the N-termi-
nus of p53 not only stabilizes p53 by abolishing its interaction
with MDM2, and regulates cellular localization by inhibiting
nuclear export, it can also stimulate the transactivation activity
of p53. Moreover, phosphorylation of p53, within its N-ter-
minus, enhances the binding between p53 and histone acetyl-
transferases (HATs) such as CREB binding protein (CBP)/
p300 and p300/CBP associated factor (P/CAF).
Whereas the N-terminus has only been shown to be
phosphorylated, the C-terminus is targeted for a variety
of posttranslational modiﬁcations. For example, a DNA
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chromatin transcriptional elongation factor is responsible for
UV-induced phosphorylation of serine 392 in the C-terminus
of p53 [27], leading to activation of DNA binding [28]. In
addition, SUMO modiﬁcations of p53 at lysine 386 also acti-
vate p53 [29–31]. As mentioned above, stress-induced acety-
lation of p53 is undertaken by HATs [32–34]. These HATs
acetylate distinct sites within the C-terminus: p300/CBP acet-
ylates lysines 373 and 382, and to a lesser extent lysines 372
and 381, whilst P/CAF recognizes lysine 320 [35]. Acetylation
of p53 increases the transcriptional activation of p53 by ac-
centuating its sequence-speciﬁc DNA-binding activity [36–39].
Recently, new evidence has come to light which challenges
this model. Several observations suggest that acetylation of
p53 promotes coactivator recruitment, rather than DNA
binding, leading to histone acetylation and transcriptional
activation of target genes. Barlev and coworkers mutated the
acetylation sites within p53, and performed chromatin immu-
noprecipitations to analyse the status of the p21 promoter in
cells. They observed that mutated p53 was defective for tran-
scriptional activation and G1 arrest, however, its DNA bind-
ing capacity was unaﬀected. Further analysis revealed that the
level of histone acetylation in the presence of acetylation-site
defective p53 was dramatically reduced compared to the level
observed in the presence of wild-type p53. Hence, they con-
cluded that p53 acetylation is required for coactivator/HAT
recruitment [40].
Interestingly independent studies, undertaken by Espinosa
and Emerson, show that p53 is an active DNA binding pro-
tein, which does not require C-terminal modiﬁcations in order
to interact with DNA. They ﬁnd that the C-terminal region
does not exert an inhibitory eﬀect, but rather is required for the
binding of p53 to certain promoters. In addition, they show
that p53 and p300 act synergistically to activate transcription,
as p300 is recruited by chromatin-bound p53, resulting in lo-
calized nucleosomal acetylation with regional spreading.
Hence, p300 mediates expression by p53-targeted nucleosomal
acetylation rather than through p53 acetylation [41]. Further
studies are required to ascertain which of these models is
correct.
Although the exact eﬀect acetylation has on the transacti-
vation activity of p53 is still under debate, the eﬀect of acety-
lation of particular lysine residues upon p53 coactivator
recruitment has been investigated. It was demonstrated that
the coactivator CBP binds speciﬁcally to acetylated lysine 382.
This interaction is responsible for p53 recruitment of CBP in
vivo upon DNA damage. This interaction appears to be cru-
cial for p53-induced transcriptional activation of p21 in cell
cycle arrest [42].
The importance of acetylation of p53 with regard to its
function was further demonstrated by reciprocal experiments,
investigating the role of histone deacetylases (HDACs) in p53
regulation. Such ﬁndings show that acetylated p53 interacts
with the nucleosome-remodelling and deacetylation complex
via its metastasis-associated-factor 2 [43]. Indeed, overexpres-
sion of MTA2 dampens both p53’s cell cycle arrest and ap-
optotic activities, presumably as a result of p53 deacetylation.
Moreover, MDM2 mediates deacetylation of p53, by recruit-
ing a complex containing HDAC1 [44]. Furthermore, overex-
pression of SIRT1, a human homologue of silent information
regulator (Sir2), deacetylates p53 and reduces p53-mediated
transactivation [45].2. Drosophila p53
2.1. Identiﬁcation of Drosophila p53
The identiﬁcation of Drosophila p53 (dmp53) was reported
by three groups [46–48]. Of the three deﬁned domains within
p53, the N- and C-termini show little conservation, the greatest
homology between p53 and dmp53 resides in the central DNA
binding domain. Indeed, dmp53 can speciﬁcally bind to a
DNA probe containing binding sites for human p53. More-
over, in transient transfection assays dmp53 can transactivate
a reporter containing human p53 binding sites. This suggests
that like human p53, dmp53 can function as a DNA binding
transcriptional activator. Further studies utilizing yeast one-
and two-hybrid assays, uncovered a transactivation domain in
the N-terminal region of dmp53, and oligomerization activities
in the C-terminal domain. Thus, human p53 and ﬂy p53 share
similar domains: an N-terminal transactivation domain, a
central DNA binding domain and a C-terminal oligomeriza-
tion domain.
2.2. In vivo function of dmp53: G1 cell cycle arrest
Within the DNA binding domain of human p53 there are
mutational hotspots, which upon being mutated result in a
dominant negative p53 protein. Introducing corresponding
mutations into dmp53 creates a dominant negative protein
that prevents wild type dmp53 from binding to DNA in vitro.
In vivo analysis to elucidate the function of dmp53 was un-
dertaken, wherein both the wild type and the dominant form
of dmp53 were overexpressed [46–48]. Overexpression of wild
type p53 does not induce G1 arrest. It fails to activate dacapo,
the Drosophila homologue of the CIP/KIP-type inhibitors re-
sponsible for p53-mediated G1 cell cycle arrest in human cells.
Moreover, expression of dominant negative dmp53 does not
interfere with X-ray irradiation induced cell cycle arrest in
third instar wing discs, suggesting that this block is dmp53-
independent. So far, there is no evidence that dmp53 shares the
ability of human p53 to induce a G1 cell cycle arrest in stressed
cells.
2.3. In vivo function of dmp53: induction of apoptosis
Overexpression of wild type dmp53 in the Drosophila eye
stimulates apoptosis. Moreover, expression of the dominant
negative dmp53 suppresses X-ray induced apoptosis in the
wing disc. The involvement of dmp53 in radiation induced
apoptosis was further conﬁrmed by analysing proapoptotic
genes, such as the reaper gene. This gene has a radiation in-
ducible control element containing a putative dmp53 response
element [46]. Yeast-one hybrid assay shows that dmp53 can
mediate transactivation from this response element, moreover,
this response element confers radiation-responsive transcrip-
tional activation upon a reporter gene in vivo. These studies
gave rise to the following model with regard to irradiation-
induced dmp53 activation: irradiation results in dmp53 acti-
vation, which can then bind and activate proapoptotic genes
such as reaper, but not cell cycle arrest genes such as dacapo.
Indeed, this model is conﬁrmed by the observation that mu-
tating dmp53 abolishes irradiation-induced apoptosis and
reaper induction [49,50].
Jassim and coworkers examined UV-mediated cell death in
the Drosophila retina. Reaper was not found to have a role
during the retina’s response to UV. Instead another proapop-
totic gene, head involution defective, was activated. Moreover,
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This was ascribed to its ability to direct DNA damage repair.
Indeed, dmp53mutants are more sensitive to UV radiation [51].ATM2.4. How is dmp53 activity regulated?
As mentioned above, one of the major determinants of p53
activity in human cells is its regulated degradation, which is
initiated by MDM2 polyubiquitination. The sequencing of the
Drosophila genome has not identiﬁed an obvious MDM2 ho-
mologue [1–3], moreover, the MDM2 binding site is not con-
served in dmp53. Curiously, however, ectopic expression of
human MDM2 does lead to apoptosis in the ﬂy but it is not
clear what the targets of MDM2 in this context are [52]. How
then is dmp53 activated following cellular insults? Are post-
translational modiﬁcations such as those which regulate p53 in
human cells involved?
The Drosophila homologue of Chk2 is required for DNA-
damage induced cell cycle arrest and apoptosis [53]. Recent
studies show that, not only does the overexpression of dmp53
in the eye result in apoptosis, but that this eﬀect is enhanced by
the coexpression of Drosophila Chk2, but not a kinase-dead
form of Drosophila Chk2 [54]. This eﬀect is speciﬁc, as the
overexpression of wild type and mutant Chk1 did not aﬀect
dmp53-induced phenotypes. No changes in dmp53 steady state
levels were detected in these experiments, suggesting that
Chk2-dependent phosphorylation of p53 might inﬂuence
properties such as DNA binding activity or interaction with
cofactors.
Recently, Brodsky and coworkers demonstrated that upon
cellular stress, dmp53 displays a phosphatase-sensitive change
in gel mobility. This was attributed to phosphorylation of p53
by the Drosophila Chk2 homologue MNK. Furthermore, no
alteration in p53 protein levels was observed, suggesting that
p53 activity can be regulated without a MDM2-like activity
[55]. A genome-wide analysis demonstrated that all IR-induced
increase in transcript levels requires both dmp53 and MNK/
Chk2. As beﬁtting the previous observations that upon stress
dmp53 does not induce cell cycle arrest, dacapo is repressed
following IR treatment. Interestingly, DNA repair genes were
also induced, such as Ku70 and Ku80 which have deﬁned
functions in DNA break repair and participate in the non-
homologous end-joining pathway [55]. These ﬁndings corrob-
orate earlier observations by Jassim and colleagues, who






















Fig. 2. Comparison of the posttranslational modiﬁcations regulating
human and ﬂy p53. There are numerous mechanisms which contribute
to the regulation of human p53 activity. In comparison dmp53 is so far
only known to be regulated by Chk2.3. Conclusion
At a ﬁrst glance it may appear that human and ﬂy p53 do
not share many structural or functional similarities, however,
close inspection reveals parallels between the two. An initial
comparison between the sequences of human and ﬂy p53
demonstrated that the greatest homology is located within the
central DNA binding domain (25% identity, 43% similarity).
In addition, this DNA binding domain is able to mimic its
human counterpart and bind human p53 response elements.
The other two functional domains, namely the N-terminal
transactivation domain and the C-terminal oligomerization
domain, do not show so much sequence homology, they do,however, perform similar activities, namely, transactivation
and oligomerization, respectively.
Moreover, like human p53, dmp53 can induce apoptosis
upon overexpression and in response to cellular insults.
However, unlike human p53, it is unable to invoke cell cycle
arrest. Perhaps cell cycle arrest has not been observed because
it is cell type speciﬁc and not all tissue types have been anal-
ysed. Despite the apparent diﬀerences in cell cycle regulation,
both human and ﬂy invoke DNA repair. As maintaining the
integrity of the genome is more important for a long living
organism, human cells are perhaps given more time to repair
DNA damage. p53’s cell cycle arrest function might have
evolved more recently (Fig. 2).
After the isolation of a p53 homologue in Drosophila,
comparison studies have been undertaken in other inverte-
brates. Caenorhabditis elegans p53 (Cep53) is a 429 amino acid
protein, which displays similarity and conservation with the N-
terminal transactivation and central DNA binding domain of
human p53, respectively. Cep53 functions both during normal
development, to ensure proper meiotic chromosome segrega-
tion, and in response to cellular stress, such as DNA damage,
starvation or hypoxia. Cep53 is ubiquitously expressed in
embryos, however, its abundance must be tightly regulated as
elevated amounts are lethal [56]. As such Cep53 is functionally
more similar to dmp53 than to human p53. Moreover, other
p53 family members have not been identiﬁed in the genomes of
either of these invertebrates, suggesting that the p63/p73 sub-
family evolved after the separation of the arthropod and ver-
tebrate lineages [48].
There is a plethora of information concerning the post-
translational modiﬁcations which target human p53, how these
are induced, and their subsequent eﬀects. In contrast, very little
is known about what modiﬁcations target dmp53 and how
they regulate dmp53 function. Recently, it was shown that
dmp53 is phosphorylated upon stress, and that modiﬁcation is
required for subsequent transactivation of genes involved in
apoptosis and DNA repair [55]. The sites within dmp53, which
are phosphorylated, are yet to be identiﬁed. Furthermore, the
molecular consequences of phosphorylation are yet to be de-
termined. However, it is not known if dmp53 is acetylated or
sumoylated. Presently, studies are being undertaken in order to
elucidate the means by which p53 decides what set of genes to
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factors which interact with p53 and target its transactivation
potential to particular genes. It is possible that such cofactors
exist in the Drosophila system. Finally, the regulation of the
cellular localization of dmp53 is yet to be elucidated.
At present therapeutic attempts to kill cancer cells use ra-
diation and chemotherapeutic agents which induce DNA
damage. This damage is recognized within the cell and the
apoptotic pathway is initiated, resulting in the oﬀending cell
being removed. However, in the majority of human cancers, a
vital component of this pathway, namely p53, is mutated. In
this form it is unable to act as a transcriptional activator and is
rendered unable to induce apoptosis. If dmp53, as the initial
observations suggest, indeed turns out to be a stable protein
that can transactivate human p53 responsive genes, there may
be therapeutic advantages to introducing dmp53 into human
cells which have lost p53 function. Dmp53 not only provides
an opportunity to extend out knowledge about the evolution
of tumour suppressors, but may aid the quest for therapeutic
alternatives.
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